{
    "clinical_study": {
        "@rank": "84164", 
        "arm_group": [
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Other", 
                "description": "Patients treated by usual customary medical practice (Usual Care)"
            }, 
            {
                "arm_group_label": "Intervention group", 
                "arm_group_type": "Other", 
                "description": "Patients treated with \"Integrated personalized diabetes management\""
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a German, prospective, multicenter, controlled, cluster-randomized,\n      interventional comparative study evaluating the efficacy and benefits of integrated PDM care\n      by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into\n      two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device."
        }, 
        "brief_title": "A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Existence of a signed Informed Consent form\n\n          -  Diagnosed Type 2 Diabetes mellitus\n\n          -  Age > / =18 years\n\n          -  Insulin therapy for >/ =6 months: Basal-supported Oral Therapy (BOT), Supplementary\n             Insulin Therapy (SIT), Conventional Insulin Therapy (CT) or Intensified Therapy (ICT)\n\n          -  HbA1c > / =7.5% within the last 6 weeks before study visit 1 (patient's inclusion)\n\n          -  Longer-term care (at least for the duration of the 12-month study participation) by\n             the trial site\n\n          -  Insured by the statutory health insurance (GKV) as a statutory or voluntarily insured\n             member or as a family co-insured member\n\n          -  Willing and able to participate in the study and to follow the study procedures,\n             among other things sufficient command of the German language, spoken and written\n\n        Exclusion Criteria:\n\n          -  Experience with structured SMBG with the use of data processing systems / software\n             e.g. the Accu-Chek \u00ae Smart Pix system and/or the Accu-Chek \u00ae 360\u00b0 diabetes management\n             software\n\n          -  Presence of terminal renal failure / dialysis and/or a loss of sight or a tumor\n             illness\n\n          -  Chronic use of steroids in adrenal suppressant doses, of other immuno-modulatory\n             drugs or chemotherapy\n\n          -  Known alcohol and drug abuse and medication abuse\n\n          -  Known metabolic disorders and/or disorders or therapies that could lead to or have\n             led to wrong measured results (e.g. with the blood glucose measurement)\n\n          -  Existing pregnancy, breast-feeding or plan to become pregnant during study\n             participation\n\n          -  Physical illness and/or psychological disorder with the result that the patient\n             cannot implement the medical treatment recommendations independently"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "540", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156349", 
            "org_study_id": "RD001732"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intervention group", 
                "description": "Blood glucose meter with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)", 
                "intervention_name": "Accu-Chek Smart Pix readout Device with Software", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Control Group", 
                "description": "Blood glucose meter with no software", 
                "intervention_name": "Accu-Chek Smart Pix readout Device", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bad Mergentheim", 
                        "country": "Germany", 
                        "zip": "97980"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buxtehude", 
                        "country": "Germany", 
                        "zip": "21614"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "21109"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kassel", 
                        "country": "Germany", 
                        "zip": "34117"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lampertheim", 
                        "country": "Germany", 
                        "zip": "68623"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Integrated Personalized Diabetes Management (Integrated PDM): Prospective, Randomized, Controlled Intervention Study for the Evaluation of the Effectiveness and the Benefit of Integrated PDM in the Care of People With Type 2 Diabetes in Diabetes Specialized Medical Practices in Germany (DSP)", 
        "overall_contact": {
            "email": "kulzer@diabetes-zentrum.de", 
            "last_name": "Bernhard Kulzer", 
            "phone": "+49 7931 /594-151"
        }, 
        "overall_official": {
            "affiliation": "Roche Diagnostics Deutschland GmbH", 
            "last_name": "Iris Vesper", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany:  Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The mean HbA1c change by means of Generalized Estimating Equations [GEE] methods", 
            "safety_issue": "No", 
            "time_frame": "from Baseline to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156349"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Diagnostics Deutschland GmbH", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}